European Journal of Rheumatology
Case Report

Recurrence of proteinuria after cessation of tocilizumab in patients with AA amyloidosis secondary to FMF

1.

Division of Rheumatology, Department of Internal Medicine, Health Sciences University Gülhane School of Medicine, Ankara, Turkey

Eur J Rheumatol 2018; 5: 278-280
DOI: 10.5152/eurjrheum.2018.17183
Read: 2357 Downloads: 1188 Published: 03 September 2019

Abstract

 

There is no established treatment protocol for amyloid-A (AA) amyloidosis secondary to Familial Mediterranean Fever (FMF). Recently, we reported the efficacy of tocilizumab in 11 amyloidosis cases associated with FMF. In 2 patients of 11, we discontinued the tocilizumab administeration owing to the normalization of amyloidosis-related symptoms, but proteinuria re-occurred eventually. Fortunately, the patients responded to tocilizumab re-treatment. This led us to conclude that physicians should not stop the treatment, even in patients with normalized proteinuria levels.

 

 

Cite this article as: Yılmaz S, Tekgöz E, Çınar M. Recurrence of proteinuria after cessation of tocilizumab in patients with AA amyloidosis secondary to FMF. Eur J Rheumatol 2018; 5: 278-80.

Files
EISSN 2148-4279